ARROWHEAD PHARMACEUTICALS, INC. Investments, Fair Value Disclosure
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Investments, Fair Value Disclosure of $40.76 million as of 2014-12-31, per its 10-Q filed 2015-02-09.
Discontinued › Notes › Fair Value Disclosures
us-gaap:InvestmentsFairValueDisclosure · last filed 2015-02-09
- 2014-12-31: Investments, Fair Value Disclosure $40.76M.
- 2014-09-30: Investments, Fair Value Disclosure $44.33M.
- 2014-06-30: Investments, Fair Value Disclosure $49.74M.
- 2014-03-31: Investments, Fair Value Disclosure $51.56M.
| Period end | Investments, Fair Value Disclosure |
|---|---|
| 2014-12-31 | $40.76M 10-Q · filed 2015-02-09 |
| 2014-09-30 | $44.33M 10-Q · filed 2015-02-09 |
| 2014-06-30 | $49.74M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $51.56M 10-Q · filed 2014-05-06 |
| 2013-12-31 | $25.53M 10-Q · filed 2014-02-04 |
| 2013-09-30 | $10.70M 10-K · filed 2014-11-25 |
| 2013-06-30 | $4.04M 10-Q · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |